Stockwatch: Hero or villain – results matter
This article was originally published in Scrip
Biogen Idec continued the good run of reports from profitable biotech companies by announcing quarterly revenues of $1.42 billion, against analysts' estimates of $1.38 billion, but missing its consensus earnings per share (EPS) target by six cents (scripintelligence.com, 29 January 2013). Last quarter's results are much more of a rear mirror view for Biogen than most other companies with the expected US and European approval of Tecfidera, formally BG-12, for multiple sclerosis (MS) looming large in their headlights.
You may also be interested in...
The Coronavirus outbreak makes its first dent into pharma's 2020 prospects as AstraZeneca admits possible impact, while could AbbVie's aesthetic plans raise the prospect of another GSK-style spin off?
Expensive acquisitions are in the spotlight during earnings season. The purchases of Kite and Celgene by Gilead and Bristol-Myers Squibb are not turning out to be what was written on the tin.
With Brexit and coronavirus depressing markets over the week, earnings season for life science companies shifted into a higher gear with a number of big companies reporting. In time, the effects of Brexit and 2019-nCoV are likely to subside, but the double-edge sword of biosimilar commercialization continues to rise from the full-year financial reports of Pfizer and Roche.